IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer (IPHC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01588964
Recruitment Status : Completed
First Posted : May 1, 2012
Last Update Posted : May 1, 2012
Information provided by (Responsible Party):
Prof. Giovanni Scambia, Catholic University of the Sacred Heart

Brief Summary:
In patient with a platinum sensitive ovarian cancer recurrence is demonstrated that the re-challenge with a compound of platinum-based, or a treatment with carboplatin in combination with paclitaxel , determines a rate of clinical response similar to the primary treatment, which is all the more important as the longer the time to progression from the primary therapy.In the clinical setting there are many studies that have shown activity of oxaliplatin and docetaxel in patients with advanced ovarian cancer. Two recent studies have shown clinical efficacy of the combination carboplatin / docetaxel in the first line oxaliplatin / paclitaxel to recurrence of disease, confirming the data already obtained from studies of activity in a single agent.In surgery it has been demonstrated in a meta-analysis including approximately 7000 patients in advanced stages of disease, that the extent of cytoreduction is the most powerful determinant of survival.The role of secondary surgical cytoreduction in case of recurrent disease has yet to be determined because of the lack of prospective randomized clinical studies that may highlight the superiority of such aggressive treatment.The combination of aggressive cytoreductive surgery and hyperthermic intraperitoneal intraoperative chemotherapy (CHIP) used in recent clinical studies showed a prolonged time to progression and disease-free survival in patients with ovarian cancer. However, these studies were conducted on groups of patients with very different among themselves and with other drugs, it is difficult to draw definitive conclusions.Given the activities of oxaliplatin and docetaxel and their non-cross-resistance we designed a Phase 2 clinical trial on treatment of patients with recurrent ovarian cancer, platinum-sensitive, treated with surgical cytoreduction with hyperthermic oxaliplatin-based intraoperative intraperitoneal chemotherapy and following consolidation treatment with oxaliplatin and docetaxel systemically every 21 days.

Condition or disease Intervention/treatment Phase
Ovarian Epithelial Cancer Recurrent Procedure: HIPEC Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Surgery and Intraperitoneal Hyperthermic Chemotherapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer .
Study Start Date : March 2005
Actual Primary Completion Date : October 2011
Actual Study Completion Date : December 2011

Arm Intervention/treatment
Experimental: HIPEC
Surgery plus HIPEC
Procedure: HIPEC
surgery plus HIPEC with the closed technique(perfusion of the abdominal cavity with a solution containing oxaliplatin 460 mg/m2 in 2L/m2 heated saline at 42°C).The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
Other Names:
  • IPHC
  • Hypertermic intraperitoneal chemotherapy

Primary Outcome Measures :
  1. Progression free survival,Overall survival, post operative complications(bowel obstruction,intestinal perforation, hemathologic toxicity (granulocytopenia,thrombocytopenia,anemia),neuropathy. [ Time Frame: 6-32 months ]
    Efficacy and tolerability of the treatment with intraoperative intraperitoneal hyperthermic chemotherapy with oxaliplatin after optimal debulking surgery in patients with platinum-sensitive recurrent ovarian cancer followed by systemic chemotherapy with docetaxel 75mg / m g1 and oxaliplatin 100 mg / m² every 21 days x g1 for six consecutive cycles.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age over 18 and under 70 years
  • Patients affected by a first recurrence of ovarian cancer with measurable lesions or not, but evaluable (upwards of Ca125 for 2 consecutive assessments).
  • ECOG-performance status ≤ 2
  • Ovarian cancer limited to the abdominal cavity with or without extraperitoneal spread considered resectable at intraoperative evaluation
  • Evidence of tumor recurrence diagnosed after 6 months from primary treatment
  • Previous-based chemotherapy of carboplatin and taxanes
  • Positive Peritoneal Washing in the presence of other abdominal disease surgically resectable
  • Adequate respiratory, hepatic, cardiac, kidney and bone marrow function (absolute neutrophil count > 1500/mm3, platelets > 150,000/μl, creatinine clearance > 60 mL/min according to Cockroft formula)
  • Patient-compliant and psychologically able to follow the trial procedures

Exclusion Criteria:

  • Non-epithelial ovarian cancer or borderline ovarian tumor
  • Pregnancy or breastfeeding
  • Patients affected by major depressive disorder even in treatment or minor mood disorders
  • Patients with severe impairment of respiratory, hepatic or renal function
  • Patients with cardiac, neurological or metabolic uncontrolled pharmacologically disease
  • Patients with active infection or other neoplastic disease in progress
  • Patients with bowel obstruction
  • Inadequate bone marrow, liver, kidney function
  • No clear-peritoneal disease at surgical exploration
  • Patients with ascites > 500 ml (the TAC)
  • Patients on maintenance therapy with Antiangiogenic drugs
  • Patients with secondary or tertiary recurrence, or already submitted to HIPEC
  • Patients who have already made the second or third line chemotherapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01588964

Sponsors and Collaborators
Catholic University of the Sacred Heart
Principal Investigator: Anna Fagotti, MD, PhD Catholic University of Sacred Heart
Principal Investigator: Gabriella Ferrandina, MD Catholic University of Sacred Heart
Principal Investigator: Ida Paris, MD Catholic University of Sacred Heart

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Prof. Giovanni Scambia, Clinical Professor, Catholic University of the Sacred Heart Identifier: NCT01588964     History of Changes
Other Study ID Numbers: Prot.lf.P.177(A.200)/C.E./2005
First Posted: May 1, 2012    Key Record Dates
Last Update Posted: May 1, 2012
Last Verified: April 2012

Keywords provided by Prof. Giovanni Scambia, Catholic University of the Sacred Heart:
ovarian cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Neoplasms, Glandular and Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms by Histologic Type